 EMERYVILLE, Calif., Jan. 11, 2021 GLOBE NEWSWIRE -- Zogenix NASDAQ: ZGNX, a global biopharmaceutical company developing and commercializing rare disease therapies, today reported select preliminary, unaudited financial results for the fourth quarter and full-year 2020. In addition, the Company highlighted its key 2021 corporate objectives. 